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ABSTRACT
Transcription factor activity is often controlled
through the dynamic use of post-translational
modifications. Two such modifications are acetyl-
ation and sumoylation, which both occur on lysine
residues, providing the opportunity for cross-talk
at the molecular level. Here, we focussed on the
ETS-domain transcription factor PEA3 and studied
the potential interplay between these two modifica-
tions. We demonstrate that PEA3 is acetylated in
a p300-dependent manner. ERK MAPK pathway
signalling potentiates acetylation of PEA3, and
enhances its trans-activation capacity. However,
the major acetylation and sumoylation events take
place on the same sites in PEA3 making simultan-
eous modification impossible. Indeed, manipulation
of either the sumoylation or acetylation pathways
causes reciprocal changes in PEA3 acetylation
and sumoylation respectively. However, despite
the mutually exclusive nature of these modifica-
tions, both contribute to the trans-activation
capacity of PEA3, implying that a dynamic series
of modification events occurs during the activation
process.
INTRODUCTION
Transcription factor function is often controlled by
post-translational modiﬁcations (1). Two such modiﬁca-
tions are acetylation and sumoylation. As acetylation and
sumoylation both occur on lysine residues, there is the
possibility of direct functional antagonism between these
post-translational modiﬁcations. Indeed there are several
examples of where this direct antagonism through modi-
ﬁcation of the same lysine residue can occur and, in
addition, where the two modiﬁcations can affect each
other in a more indirect manner (reviewed in 2–6).
However, in contrast to these antagonistic functions,
little is known about how acetylation and sumoylation
might cooperate to either repress or activate transcription.
SUMO is a small polypeptide which is structurally
related to ubiquitin, and is conjugated to substrates
through a pathway composed of proteins, which show
structural and functional homology with the ubiquitin
pathway (reviewed in 7,8). Sumoylation is reversible,
resulting in a dynamic process, which can be controlled
in a number of ways such as through the action of protein
kinase cascades (reviewed in reviewed in 8,9). For
example, HSF-1 sumoylation status is enhanced following
heat shock-mediated phosphorylation of an extended
SUMO recognition motif known as the phosphorylation-
dependent sumoylation motif (PDSM) (10). This motif
contains a proline-directed serine phosphorylation site
located three amino acids downstream from the core con-
sensus sumoylation motif (cKxExxSP). Sumoylation can
cause changes in protein function in many different ways
but in the case of transcription factors, it usually results in
imparting repressive properties on transcriptional regula-
tory proteins (reviewed in 11,12). However, sumoylation
can also result in transcriptional activation (reviewed in
13). Recently this was shown to be the case for the ETS-
domain transcription factor PEA3 where sumoylation was
not only required for efﬁcient PEA3-mediated transcrip-
tional activation but also for RNF4-directed
ubiquitination and degradation of PEA3 (14).
PEA3 (also known as E1AF and ETV4) along with
ER81/ETV1 and ERM/ETV5 are members of a subfamily
of E-twenty six (ETS)-domain transcription factors. These
three transcription factors share a common domain struc-
ture and exhibit extensive sequence similarity (reviewed in
15). Biologically, PEA3 subfamily members are often
associated with cancer and in particular with the metastat-
ic phase (reviewed in 15). During normal development,
PEA3 has a role in neuronal pathﬁnding (16) and
mammary gland development (17). PEA3 functions as
a transcriptional activator protein and its trans-activation-
capacity is enhanced following activation of the ERK
and JNK MAP kinase signalling pathways (18).
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cascades, which cooperate with the acetyl transferases
PCAF and p300 to potentiate its trans-activation
capacity (19). In the case of PEA3, sumoylation is
enhanced by ERK MAP kinase signalling, and this
contributes to the activating effect of this pathway (14).
A common unifying theme applying to PEA3 subfamily
members appears to be the induction of a range of
post-translational modiﬁcations such as acetylation and
sumoylation by MAP kinase signalling. No links
between these modiﬁcations within this subfamily have
been studied. However, in other proteins such as HIC1,
an extended core sumoylation motif (cKxEP) directs
antagonistic acetylation and sumoylation of the
embedded lysine residue (20). Here, we focussed on
PEA3 and demonstrate that it is acetylated in a
p300-dependent manner. This acetylation is potentiated
by ERK MAPK pathway signalling, and enhances the
trans-activation capacity of PEA3. Importantly, acetyl-
ation and sumoylation take place on the same sites in
PEA3 making simultaneous modiﬁcation impossible.
Indeed, experimental manipulation of either the
sumoylation or acetylation pathways causes reciprocal
changes in PEA3 acetylation and sumoylation respective-
ly. Despite the mutually exclusive nature of these modiﬁ-
cations, both contribute to the trans-activation capacity of
PEA3 and lie downstream of ERK pathway signalling,
implying that a dynamic series of modiﬁcation events
occurs during the activation process.
MATERIALS AND METHODS
Plasmid constructs
The following plasmids were used in mammalian cell
transfections. pCH110 (Pharmacia), p5xPEA3 RE-Luc
(5  PEA3/ETS binding sites and AdML promoter; 21),
pColI-Luc [containing the MMP1 promoter ( 517/+63);
kindly provided by Olivier Kassel; (22)] and phPES2
(nucleotides  1432 to +59 of human COX-2 promoter;
23) have been described previously. pAS1801 (encoding
full-length mouse PEA3) (24), pKW2T-HA-PIASy
(kindly provided by Frances Fuller-Pace), pCDNA3-
Ubc9 and pCDNA3-His-SUMO-2 (kindly provided by
Ron Hay), pCMV-p300 and pCMV-p300HAT [kindly
provided by Michael Brattain; (25)] and Flag-E1AF
(encoding human PEA3) [kindly provided by Tamotsu
Nishida; (26)] have been described previously. pCMV-
MEK1 encodes constitutively active MEK-1
(NS218E-S222D).
The following plasmids encoding full-length PEA3 with
mutations in combinations of the lysine residues K96
(K1), K222 (K2), K256 (K3), K328 (K4), K437 (K5) or
glutamate residues E98 (E1), E224 (E2), E258 (E3), E330
(E4), E439 (E5) were described previously (14). pAS1043,
pAS1050 pAS1029, pAS1030, pAS1031, pAS1032
pAS1034 pAS2651 pAS1040 pAS1042 and pAS1041
[encode PEA3(E1A), PEA3(E12345A), PEA3(K1R),
PEA3(K2R), PEA3(K3R), PEA3(K4R), PEA3(K12R),
PEA3(K1345R), PEA3(K1234R), PEA3(K2345R) and
PEA3(K12345R), respectively]. pAS1037, pAS1038,
pAS1039, pAS1040, pAS4051 and pAS4053 [encoding
PEA3(K34R), PEA3(K134R), PEA3(K234R), PEA3
(K1234R), PEA3(K1Q) and PEA3(K12Q), respectively]
were constructed using the appropriate primer pairs
(14), ADS4057/ADS4058 (K1Q), or ADS4059/ADS4060
(K2Q) on templates already containing individual or
multiple mutations.
For bacterial expression, pGEX-KG-PEA3(1-335)
(pAS2502) was constructed by inserting a BamHI/
EcoRI-cut PCR product (generated using the primer
pair ADS1580/ADS1582 on the template pAS1801) into
the same sites in pGEX-KG.
Tissue culture, cell transfections, reporter gene assays
and RT–PCR
HEK293 and F9 cells were grown in DMEM supple-
mented with 10% foetal bovine serum. Where indicated,
cells were treated with phorbol 12-myristate 13-acetate
(PMA) (10nM), the MEK inhibitor U0126 (10mM),
TSA (200nM) or the proteosome inhibitor MG132
(5mM). Plasmid transfections for HEK293T cells were
performed using Polyfect (Qiagen) according to the manu-
facturer’s instructions. SiRNA transfections were general-
ly performed with 5ml lipofectamine 2000 per well in a
6-well plate and 40nM SMARTpool siRNA duplexes
against PCAF and p300 or a scrambled duplex
(Dharmacon). For p300 knockdown in COX-2 promoter
studies Lipofectamine RNAiMAX (Invitrogen) was used
by adding 2ml of p300 siRNA (10mM) to 200mlo f
Opti-MEM I medium without serum to a 12 well tissue
culture plate, mixed gently with 2ml of Lipofectamine
RNAiMAX and left to incubate for 10–20min at room
temperature. Diluted 293T cells were added to each well.
After 24h, phPES2 and PEA3 expression plasmids were
transfected using Polyfect (Qiagen). After another 24h,
cells were harvested and used for luciferase assays.
For reporter gene assays, typically 0.25mg of reporter
plasmid and 50ng of pCH110 were co-transfected with
0.005–2mg of expression plasmids. Cell extracts were
prepared and equal amounts of protein were used in
luciferase and b-galactosidase assays as described previ-
ously (24). Real-time RT–PCR was performed as
described previously using the primer pairs ADS1962/
ADS1963 to detect MMP-1 expression (14). MMP-1
levels were normalized to 18S RNA levels.
In vivo SUMO assays
In vivo sumoylation of overexpressed proteins was
detected by co-transfection of His-tagged SUMO-2 and
Ubc9 and wild-type (WT) or mutant PEA3 derivatives
into 293T cells. Cell lysates were made under denaturing
conditions in the presence of 8M guanidine–HCl, and
10mM imidazole and sumoylated conjugates isolated by
Ni-afﬁnity chromatography as described previously (27).
In vitro acetylation assays
For in vitro acetylation assays,  2mg of GST-PEA3 fusion
protein or histones were added to 20ml reactions contain-
ing 250mM Tris pH 8.0, 25% glycerol, 250mM KCl,
0.5mM EDTA, 1mM DTT, 10mM sodium butyrate,
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14C]acetyl-CoA (59mCi/mmol) and  100ng
p300 (HAT domain) (Millipore). The samples were
incubated at 30 C for 2h then terminated by adding
5ml SDS loading buffer and boiling before subjecting
to SDS–PAGE.
14C-labelled bands were visualized by
phosphorimaging and analysed using Quantity One
software (Biorad).
Western blot and co-immunoprecipitation analysis
Western blotting was carried out with the primary
antibodies; PEA3 (Santa Cruz, sc113), Flag (Sigma),
anti-acetyl lysine (Ab409-200; Abcam), anti-HA (Cancer
Research UK), GAPDH (Abcam) and p300 (Santa Cruz,
N-15) essentially as described previously (24). Data were
quantiﬁed using Quantity One software (Biorad).
Co-immunoprecipitation of overexpressed proteins was
performed as described previously (24). To perform
co-immunoprecipitations of endogenous proteins from
F9 cells and to precipitate PEA3 for subsequent analysis
of acetylation levels, we followed the method essentially as
previously described (28). To enhance the stability of
PEA3 in F9 cells, cells were pre-treated with MG132 for
6h. Brieﬂy, the cell pellets were resuspended in 2 pellet
volumes of Buffer A (20mM HEPES, pH 7.9, 10mM
NaCl, 3mM MgCl2, 0.1% NP-40, 10% glycerol, 0.2mM
EDTA, plus protease inhibitors) and left on ice for
10–15min with occasional tapping. The nuclei were
pelleted by spinning down at 2000rpm for 5min at 4 C.
The nuclei were washed with 3 pellet volumes of Buffer B
(20mM HEPES, pH 7.9, 20% glycerol, 0.2mM EDTA,
protease inhibitors) and centrifuged again. The pelleted
nuclei were then resuspended in one pellet volume of
Buffer C (20mM HEPES, pH 7.9, 400mM NaCl, 20%
glycerol, 0.2mM EDTA, plus protease inhibitors) and
agitated for 45min at 4 C. After centrifugation for
15min at 13000rpm, the supernatants were diluted to
one ml with washing buffer (pH 7.5, 20mM Tris–HCl,
150mM NaCl). PEA3 antibody was added, incubated
overnight at 4 C. The following day Protein G beads
(Sigma) were added and incubated for 2h and then
washed with washing buffer four times.
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation (ChIP) assays using
anti-HA antibody were performed as described previously
(14). Bound promoters were detected by PCR using
primers for the promoter region (ADS1277/ADS1278) or
coding (ADS1279/ADS1280) region of p5xPEA3 RE-Luc
(24). ADS1968, 50-GGGGACTCCAAGGCTCTATT-30
and ADS1969, 50-TCAGGAAAGCAGCATGTGAC-30.
Sample preparation, mass spectrometry and data analysis
Four 10cm dishes of 293 cells co-transfected with expres-
sion vectors for PEA3 and p300 were serum starved for
24h, then stimulated with PMA 6h. PEA3 was then
immunoprecipitated, subjected to SDS–PAGE and the
region of the gel corresponding to the location of the
PEA3-speciﬁc band was excised. Samples were reduced,
alkylated with iodoacetamide, and then digested overnight
with trypsin, GluC or GluC and LysC. Digested samples
were analysed by LC-MS/MS using a NanoAcquity
LC (Waters, Manchester, UK) coupled to a LTQ
Velos (Thermo Fisher Scientiﬁc, Waltham, MA, USA).
Peptides were concentrated on a pre-column (20mm 
180mm i.d., Waters). The peptides were then separated
using a gradient from 99% A (0.1% FA in water) and
1% B (0.1% FA in acetonitrile) to 30% B, in 40min at
200nlmin
 1, using a 75mm 250mm i.d. 1.7mM BEH
C18, analytical column (Waters). Peptides were selected
for fragmentation automatically by data-dependant
analysis.
Data produced were searched using Mascot (v 2.2,
Matrix Science, UK), against the IPI Mouse database
with the appropriate enzyme selected, carbamido-
methylation of cysteines and acetylation of lysines
selected as ﬁxed and variable modiﬁcations, respectively.
Data were then validated using Scaffold (Version 3,
Proteome Software, Portland, OR) and identiﬁed sites of
modiﬁcation conﬁrmed by manual inspection of product
ion spectra.
RESULTS
PEA3 is acetylated by p300
The PEA3 subfamily member ER81 has been shown to be
acetylated by both p300 and PCAF (19). Here we tested
whether PEA3 is also acetylated. Endogenous PEA3 is
expressed in mouse embryonic carcinoma F9 cells (29)
and was precipitated using and anti-PEA3 antibody and
acetylation detected using an anti-acetyl lysine antibody.
Two bands corresponding to PEA3 were identiﬁed, and
acetylation of the upper band was detected (Figure 1A).
We also asked whether acetylation of exogenous PEA3
could also be detected by transfecting HEK293 cells
with a mouse PEA3 expression vector. Weak acetylation
was detected but this could be signiﬁcantly enhanced
through either treatment of the cells with either PMA or
with the histone deacetylase (HDAC) inhibitor TSA
(Figure 1B). TSA treatment alters the dynamics of
acetylation by inhibiting the activity of Class I and II
HDACs while PMA is known to enhance the
trans-activation activity of PEA3 in an ERK MAP
kinase pathway-dependent manner (14). The enhancement
of PEA3 acetylation by PMA is also dependent on ERK
pathway signalling as the MEK inhibitor U0126 reduces
the amount of inducible PEA3 elicited by PMA treatment
(Figure 1C). The identity of the acetyl transferase
responsible for PEA3 acetylation was probed by
siRNA-mediated depletion of PCAF or p300. These
experiments were carried out in the presence of PMA to
activate the ERK pathway. Depletion of p300 caused
a substantial decrease in PEA3 acetylation levels
whereas depletion of PCAF had little effect on PEA3
acetylation (Figure 1D), thereby speciﬁcally implicating
p300 in PEA3 acetylation. This link was further
investigated by overexpression of p300 which resulted in
enhanced acetylation of PEA3 both in the absence of
ERK pathway activation (Figure 1E, lane 3) or when
this pathway is activated by co-transfection of constitu-
tively active MEK (Figure 1F, lane 4). Importantly, the
Nucleic Acids Research, 2011,Vol.39, No. 15 6405catalytic activity of p300 is required, as a mutant version
lacking the histone acetyltransferase domain (HAT) is
unable to potentiate PEA3 acetylation (Figure 1F, lane 5).
To determine whether p300 can directly acetylate PEA3,
we tested the ability of recombinant p300 HAT domain
to acetylate a puriﬁed truncated version of PEA3
[GST-PEA3(1-335)] which contains the N-terminal part
of PEA3 that precedes the ETS DNA binding domain.
Acetylation of PEA3 was detectable in this assay
(Figure 1G). Finally we asked whether p300 could bind
to PEA3. Endogenous PEA3 was precipitated from F9
cells and p300 was found to co-precipitate with PEA3
(Figure 1H).
Together these results demonstrate that PEA3 is
acetylated in a p300-dependent manner and this acetyl-
ation is enhanced following ERK pathway activation.
p300 promotes transcriptional activation by PEA3
To study transcriptional activation by PEA3 in the
absence of other promoter-bound transcription factors,
we used a luciferase reporter construct driven by a basal
promoter and ﬁve reiterated ETS binding motifs. PEA3 is
sufﬁcient to enhance the activity of this reporter construct
but this activity is substantially increased by either
co-expression of a constitutively active form of MEK to
activate the ERK pathway or the acetyl transferase p300
(Figure 2A; Supplementary Figure S1). Co-transfection
of expression vectors encoding PEA3, MEK and p300
further increased the reporter activity in a synergistic
manner (Figure 2A). To probe whether the acetyl-
transferase activity of p300 was required for enhancing
the trans-activation capacity of PEA3, we compared the
effect of WT p300 and p300HAT which lacks its HAT
domain. While WT p300 potentiated PEA3-mediated
trans-activation, no such increase was observed with
p300HAT (Figure 2B). Conversely, we removed
endogenous p300 through siRNA-mediated depletion.
The loss of p300 ablated PEA3-mediated transcriptional
activation whereas PCAF depletion had little effect
(Figure 2C). Finally, we asked whether p300 can also
affect the activity of PEA3 on one of its target genes,
MMP-1. p300 was able to promote PEA3-mediated acti-
vation of both a luciferase reporter driven by the MMP-1
promoter (Figure 2D) and PEA3-mediated expression of
D A
G
B
PEA3 ETS Ct AD
AD PEA3(1-335)
PEA3-IB
PEA3-IP
Ac-Lys-IB
IgG
PEA3
IP
*
*
E
PEA3-IP
Ac-Lys-IB
PEA3-IP
PEA3-IB
- ++ PEA3:
- + p300: -
*
- ++++ MEK:
PEA3-IP
PEA3-IB
- - +++ PEA3:
- - + p300DHAT: --
- ++ p300: --
p300-IB
*
PEA3-IP
Ac-Lys-IB
F
123 45
123
12
PEA3
PEA3-IB
p300-IB
IgG
IP
*
H
12
C
PMA
TSA
PEA3-IB 
PEA3-IP
Ac-Lys-IB
-
123
- ++ PMA:
- + U0126: -
PEA3-IB 
PEA3-IP
Ac-Lys-IB
123
p300
PEA3
1234
- ++ PEA3: +
p300: + -
1x 2.3x 2.5x
1x 0.54x
GAPDH
- siRNA:
p300-IB
PCAF-IB
PEA3 & PMA
PEA3-IP
Ac-Lys-IB
PEA3-IP
PEA3-IB
PCAF
p300
Figure 1. PEA3 is acetylated by p300. (A) Endogenous PEA3 was immunoprecipitated IP from F9 cells with anti-PEA3 antibody or non-speciﬁc IgG
and resulting bands were detected by immunoblotting (IB) using anti-PEA3 or anti-acetyl lysine (Ac-Lys) antibodies. (B–F) HEK293 cells were
transfected with a PEA3 expression vector, followed by IP with anti-PEA3 antibody and IB with either anti-PEA3, acetyl lysine, or p300 antibodies.
Cells were treated with (B) PMA or TSA for 6h, (C) PMA for 6h, (D) siRNAs against p300 or PCAF, (E and F) cotransfection with p300 and
p300HAT expression vectors. Where indicated, cells were treated with PMA (D) or a vector encoding constitutively activated MEK was
co-transfected (F). Bands corresponding to full-length (black arrow) and HAT (grey arrow) versions of p300 are indicated in (F).
Quantiﬁcation of the level of PEA3 acetylation (normalized for total PEA3 levels) is shown below the ﬁgures relative to the amount in the
absence of treatment (B) or the presence of PMA (C) (taken as 1). (G) In vitro acetylation assays of GST-PEA3(1-335) with recombinant p300
catalytic domain. A phosphorimage showing
14C-labelled acetylated species is shown. Arrows indicate the location of bands corresponding to p300
autoacetylation (grey) and acetylated PEA3 (black). The schematic diagram shows the fragment of PEA3 used here (1-355) compared to full-length
PEA3. (H) Co-immunoprecipitation analysis of endogenous PEA3 with endogenous p300 from F9 cells. IP was performed with non-speciﬁc IgG or
an anti-PEA3 antibody and IB with either anti-PEA3, or p300 antibodies. Bands corresponding to PEA3 are indicated by arrows. Asterisks indicate
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6406 Nucleic Acids Research, 2011,Vol.39, No. 15the endogenous MMP-1 gene (Figure 2E). We also per-
formed ChIP analysis of HA-tagged p300 binding to the
luciferase reporter construct to probe the role of PEA3 in
p300 recruitment. p300 binding to the promoter region
was strongly enhanced upon co-transfection of PEA3
(Figure 2F, lane 3) but little binding was visible when
non-speciﬁc IgG was used (Figure 2F, lane 2) or binding
to the luciferase coding region was analysed (Figure 2F,
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Nucleic Acids Research, 2011,Vol.39, No. 15 6407middle panel). Furthermore, p300 potentiated the activity
of PEA3 on another target gene COX-2 (data not shown)
and, conversely, depletion of p300 reduced the ability of
PEA3 to activate the COX-2 promoter (Figure 2G).
Collectively, this combination of overexpression and
knockdown experiments demonstrate that p300 plays
an important role in PEA3-mediated transcriptional
activation.
Mapping the p300-mediated acetylation sites in PEA3
To further study the functional importance of
p300-mediated acetylation events, we mapped the acetyl-
ation sites in PEA3. HEK293 cells were co-transfected
with PEA3 and p300, extracts were separated by SDS–
PAGE and regions corresponding to the predicted
location of PEA3 were excised, subjected to proteolytic
digestion and analysed by mass spectrometry. Ten differ-
ent sites of acetylation could be identiﬁed (Figure 3A).
Interestingly, three of these are on lysines (K96, K256
and K437) which conform to the core consensus
sumoylation site cKxE (Figure 3A), and two of these,
K96 and K256 were recently shown to be modiﬁed by
SUMO in vivo (14,26,30). This suggested a possible inter-
play between these two modiﬁcations, so we focussed on
the ﬁve lysine residues embedded within core SUMO
motifs, and mutated these individually and in combination
(Figure 3B). WT and mutant PEA3 proteins were then
tested for p300-mediated acetylation in vivo. Mutation of
all ﬁve lysine residues resulted in virtually a complete loss
of PEA3 acetylation (Figure 3C, lanes 6 and 7). However,
in comparison, mutation of the ﬁve glutamic acid residues
in the core sumoylation motif caused a much less dramatic
change in acetylation levels (Figure 3C, lanes 4 and 5).
This mutant exhibits substantially reduced sumoylation
levels (14), suggesting that efﬁcient sumoylation is not
a prerequisite for subsequent PEA3 acetylation. Further
combinations of four lysine mutations also led to substan-
tial decreases in acetylation, whereas triple and double
mutations had variable effects with mutation of the ﬁrst
two lysine residues having the biggest effect (Figure 3D).
These results therefore demonstrate that p300-mediated
acetylation of PEA3 takes place at a set of sites that
overlap with sites that are also subject to sumoylation.
Multiple sites appear to be important for acetylation
with K96 and K222 playing the most prominent roles.
Mapping the p300 binding determinants in PEA3
Next we wished to determine whether the lysine residues in
PEA3 played a role in p300 binding. Again we focussed on
the lysine residues embedded in the core sumoylation
motifs. Mutation of all ﬁve lysine residues in PEA3
resulted in virtually a complete loss of p300 binding
(Figure 4A, lanes 7 and 8). However, mutation of the
ﬁve glutamic acid residues in the core sumoylation motif
only slightly reduced p300 binding (Figure 4A, lanes 5 and
6). The acetyltransferase activity of p300 was unimportant
for this binding as p300HAT bound efﬁciently to PEA3
(Figure 4B). Next, we further delineated the lysine residues
required for p300 binding through analysing a series of
double and single mutant proteins. The ﬁrst two lysine
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mutant PEA3 proteins, the indicated combinations of MEK and p300
expression vectors. The asterisk indicates bands arising from
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binding, whereas the third and fourth lysines played
lesser roles (Figure 4C). Of these ﬁrst two residues, the
ﬁrst, K96, was the most critical for p300 binding as
mutation of this residue on its own substantially reduced
p300 binding (Figure 4D). K96 in PEA3 is therefore
important speciﬁcally for p300 binding. To test whether
this residue is sufﬁcient for p300 binding, we mutated all
the other lysine residues embedded within SUMO consen-
sus motifs and tested for p300 binding. This mutant,
PEA3(K2345R) was still able to efﬁciently bind to p300,
in contrast to other mutants retaining either the second or
ﬁfth lysine residues, which exhibited much reduced
binding to p300 (Figure 4E).
Together, these results demonstrate an important role
for K96 in PEA3 for binding to p300, and further dem-
onstrate that the requirements for p300 binding closely
mirror the requirements for p300-mediated acetylation.
The role of p300 acetylation sites in PEA3-mediated
transcriptional activation
To probe the role of the acetylation sites in
PEA3-mediated trans-activation, we used a reporter
assay system to assess the ability of p300 to potentiate
the activity of a panel of PEA3 mutants in the context
of reiterated PEA3 binding elements. The mutation of
all ﬁve lysine residues embedded in sumoylation motifs
caused a reduction in p300-mediated increases in PEA3
activity (Figure 5A). However, the equivalent mutant
which destroys the core SUMO motifs by removing the
glutamic acid residues, had little effect on p300-mediated
trans-activation levels (Figure 5A), demonstrating that the
loss of sumoylation was not the reason for the reduced
activity. Further mutations of individual lysine residues
had variable effects on p300-mediated potentiation of
PEA3 activity (Supplementary Figure S2A) whereas
compound sets of four mutations severely affected the
activity of p300 towards PEA3 in this context
(Supplementary Figure S2B). The combination of
mutating K96 and K222 in the PEA3(K12R) mutant
had the biggest effect on reducing PEA3 acetylation
(Figure 3) and p300 binding (Figure 4) and individual
mutations at these sites had a moderate effect on PEA3
activity (Supplementary Figure S2A). We therefore
compared the ability of the K12R mutant and K34R
mutant forms of PEA3 to activate transcription in the
presence of p300. While the K34R mutant showed virtu-
ally WT activity, the K12R mutant exhibited a substantial
reduction in its trans-activation capacity (Figure 5B).
Thus, the loss of acetylation and p300 binding in the
K12R mutant correlates strongly with the loss of
trans-activation capacity. Conversely, we also introduced
glutamine residues in place of K96 and K222 in the K12Q
mutant form of PEA3 to mimic acetylation. Mutation of
K96 to glutamine caused a small increase in PEA3 activity
(data not shown). However, the K12Q mutant form of
PEA3 exhibited substantially elevated levels of transcrip-
tional activity (Figure 5C), further underscoring the
importance of acetylation at these two residues.
K96 was shown to be sufﬁcient among the ﬁve lysines
tested for binding to p300 (Figure 4), therefore we asked
whether this residue might be sufﬁcient for providing
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Nucleic Acids Research, 2011,Vol.39, No. 15 6409normal levels of PEA3-mediated trans-activation. Indeed,
in the presence of p300, the K2345R mutant (which
retains only K96) exhibited nearly WT activity whereas
the K1234R mutant (which retains only K437) showed
greatly reduced activity (Figure 5D; Supplementary
Figure S2B).
These results demonstrate that at the functional level,
multiple lysine residues contribute in a combinatorial
manner to p300-mediated transcriptional activation
through PEA3, and in particular point to a prominent
role for K96, in combination with K222.
The interplay between acetylation and sumoylation
The results so far clearly demonstrate an important role
for lysine residues embedded within core sumoylation con-
sensus motifs (Figure 3A) in p300-mediated acetylation
events. As at least two of these sites, K96 and K256, are
acetylated (Figure 3A) and sumoylated (14), this suggests
that these modiﬁcations must be mutually exclusive
events. To test whether this was the case, we ﬁrst moni-
tored the kinetics of PEA3 acetylation and sumoylation
following the stimulation of cells with PMA. Signiﬁcant
increases in both acetylation and sumoylation of PEA3
could be detected 30min after PMA stimulation
(Figure 6A, middle and top panels, respectively).
Acetylation and sumoylation then continued to rise over
a 6-h period, most notably for sumoylation (Figure 6A;
Supplementary Figure S3). Thus kinetically the two modi-
ﬁcations initially follow similar time courses, although
the relative levels of sumoylation appear to be greatly
enhanced at later timepoints. Next, we overexpressed
p300 and monitored PEA3 sumoylation levels. p300
caused a reduction in sumoylation levels as would be
predicted if the same sites are being modiﬁed (Figure 6B
and D). Moreover, the HAT activity of p300 is required
for inhibiting sumoylation (Figure 6C), thereby ruling
out a steric hindrance model where p300 binding
would occlude access for the sumoylation machinery.
Furthermore, we tested whether raising the acetylation
levels in cells by using the HDAC inhibitor TSA would
result in reduced sumoylation. Again, this mode of
increasing acetylation resulted in a severe reduction in
sumoylation levels, which was especially noticeable in
the bottom sumoylation band which corresponds to
sumoylation of K96 [Figure 6D; (14)]. Conversely, we
raised the levels of PEA3 sumoylation by overexpressing
components of the SUMO machinery and assessed the
impact on PEA3 acetylation. As PEA3 sumoylation
levels were increased, PEA3 acetylation levels were
decreased (Figure 6E, lanes 2 and 3).
Together, these results demonstrate the mutually exclu-
sive modiﬁcation of PEA3 by sumoylation and acetylation
and suggest that these modiﬁcations are dynamically
regulated.
DISCUSSION
Sumoylation has emerged as an important post-
translational modiﬁcation of transcription factors which
can change their activities (reviewed in 13). However, it is
becoming increasingly recognized that sumoylation is
often a transient modiﬁcation and can be dynamically
regulated such as after the activation of intracellular
signalling pathways (9). Part of this dynamism can poten-
tially be achieved through competing modiﬁcations for the
same lysine residue. This has been demonstrated to occur
in several proteins such as HIC1where antagonistic acetyl-
ation and sumoylation occurs on a lysine residue (20).
Similarly, MEF2A is modiﬁed by SUMO and acetylation
at the same residue, and in this case, dephosphorylation
of MEF2A by calcineurin promotes a switch from
sumoylation to acetylation (31). In the case of HIC1, the
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Figure 5. The role of acetylated lysine residues in p300-mediated
potentiation of PEA3 activity. (A–D) Reporter gene analysis using a
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where two parts of a gel have been rejoined).
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lished with switching from SUMO-dependent recruitment
of the corepressor NuRD to loss of this corepressor upon
acetylation (6). Here we show that the ETS-domain tran-
scription factor PEA3 is subject to complex regulation by
acetylation and sumoylation as it is also acetylated
and sumoylated on the same lysine residues in a
signal-dependent manner.
PEA3 is modiﬁed by acetylation and this is mediated by
the acetyl transferase p300 (Figure 1). This effect appears
speciﬁc as neither PCAF (Figure 1D) nor CBP (data not
shown) appear to play major roles in PEA3 acetylation.
Furthermore, PCAF does not appear to affect PEA3
function either as depletion of PCAF has little effect on
PEA3-driven reporter gene activation (Figure 2). This
contrasts with the related transcription factor ER81,
where both p300 and PCAF appear to be involved (19).
Indeed, of the two sites identiﬁed in ER81 as important
for acetylation, by p300 (K33 and K116), only K38
(equivalent to K33 in ER81) was identiﬁed in PEA3 by
mass spectrometry as a p300-dependent acetylation site,
and mutation of this site had no functional consequence
(data not shown). The other lysine residue in ER81
(K116), equivalent to amino acid 123 in PEA3, does not
appear to be conserved and is replaced by a glutamine
residue in PEA3, which is often used as an
acetylation-mimic and hence might mimic a constitutively
acetylated state. Thus, the regulation of PEA3 by acetyl-
ation appears to be substantially different to ER81.
Instead PEA3 acetylation takes place on numerous
residues of which several overlap with the sites corres-
ponding to lysines embedded in SUMO consensus motifs
(Figure 3). Subsequent analysis demonstrated that
amongst these sites, K96 appears to be one of the most
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binding, suggesting that it might act as a nucleating event
for progressive PEA3 acetylation (Figure 4). It is therefore
not clear what role acetylation at the other lysine residues
plays in PEA3 function. However, the virtual complete
loss of acetylation upon mutation of the ﬁve lysines
embedded in SUMO consensus motifs (Figure 3C),
suggests that the additional seven sites identiﬁed by mass
spectrometry, which do not ﬁt this category, are likely
only present in sub-stoichiometric amounts. In addition
to the sites identiﬁed by mass spectrometry, K222 also
appears to be of particular importance in acetylation-
dependent activities and functions alongside K96
(Figure 5). Thus while K96 in PEA3 is important and
sufﬁcient for many of the acetylation dependent activities,
there appears to be a degree of functional redundancy
with K222.
Lysine 96 is interesting as it is located within the
consensus PDSM sumoylation motif (cKxEPxSP) which
represents an extension of the core consensus motif. This
motif is found in proteins such as MEF2A which
are subject to control by phosphorylation (through
proline-directed phosphorylation of the SP motif) and
antagonistic modiﬁcation by acetylation (31). The
proline residue at position 5 appears important for the
antagonism between sumoylation and acetylation (20).
We previously demonstrated that the SP motif is import-
ant in promoting PEA3 sumoylation, thereby implicating
proline-directed kinases in its regulation (14). Importantly
though, activation of sustained ERK pathway signalling
by PMA treatment activates both sumoylation [Figure 6;
(14)] and acetylation (Figure 6) with similar kinetics. It is
not yet clear whether this motif directs these events but it
might be a contributory factor. Importantly though, as the
induction of acetylation and sumoylation occurs with
similar kinetics, this implies rapid dynamic interconver-
sion of modiﬁcation of distinct populations of molecules.
By increasing the levels of acetylation or alternatively
sumoylation, antagonistic effects are generated on
overall PEA3 sumoylation and acetylation levels as
might be expected from sharing the same modiﬁcation
sites (Figure 6). Thus it is clear that acetylation and
sumoylation cannot co-exist on the same sites but as
PEA3 contains three major acetylation sites, it is
possible that molecules containing mixtures of acetylated
and sumoylated residues might exist, and might represent
transitions between fully acetylated and sumoylated states.
Mechanistically, the antagonism seen by sumoylation of
PEA3 might work similarly to sumoylation of PARP-1
which stops p300 from acetylating adjacent lysine
residues (4), although this appears unlikely as the same
residues are targets for both acetylation and sumoylation
in PEA3. Importantly however, the occurrence of acetyl-
ation and sumoylation does not always imply functional
antagonism as a similar interplay between acetylation and
sumoylation was not evident with PGC-1a (32).
Together, our results enable us to build a model for how
different post-translational modiﬁcations impact on PEA3
activity (Figure 6F). First activation of the ERK MAP
kinase pathway causes PEA3 phosphorylation (18) and
leads to enhancement of acetylation and sumoylation. It
is not known whether phosphorylation is retained along-
side sumoylation and/or acetylation. Both sumoylation
and acetylation are associated with increased PEA3
activity. Thus, a sequential series of modiﬁcations by
acetylation then sumoylation would be consistent with
this common functional endpoint. It should however be
noted that there are many possible intermediary scenarios
due to the large number of acetylation and sumoylation
events, so molecules with mixed populations of acetyl-
ation are likely (i.e. the model in Figure 6G is an
over-simpliﬁcation showing theoretical points where
sumoylation would replace each of the acetylation events
at the SUMO consensus motifs only). In one possible
scenario, acetylation would either prime PEA3 for
sumoylation, or alternatively would set a threshold
whereby high levels of sumoylation would be needed to
overcome the acetylation events. Such a scenario would
occur on the lysine residues which are modiﬁed by either
acetylation or sumoylation and would be consistent with
the antagonism seen when manipulating either pathway
(Figure 6). Conversely, it appears unlikely that
sumoylation is required for acetylation as a PEA3
protein with mutations of the glutamic acid residues in
all the core sumoylation motifs is still efﬁciently
acetylated. However, this mutant does retain some
sumoylation (unlike the equivalent lysine residue
mutant) (14), and there is a reduction in acetylation
levels, thus it remains possible that this basal level
sumoylation might be sufﬁcient to couple with acetylation
events. This type of coupled regulation between acetyl-
ation and sumoylation has been proposed for p53 where
sumoylation at K386 blocks subsequent acetylation by
p300, but p300-acetylated p53 remains permissive for
ensuing sumoylation at K386 (5). Sumoylation of PEA3
ultimately leads to the recruitment of RNF4 and its
subsequent polyubiquitination and degradation (14).
However, we cannot rule out that two parallel paths
exist for PEA3 activation, one through acetylation and
one through sumoylation. Indeed, mutating K96 and
K222 to glutamine (i.e. mimicking acetylation) is sufﬁcient
to promote enhanced trans-activation by PEA3, which
implies that subsequent sumoylation (at least not at
these two sites) is not required for at least part of the
acetylation-mediated increase in PEA3 activity. It is
however clear that the regulatory events initiated by
ERK MAP kinase signalling that impact on PEA3
function are complex and imply a large degree of
dynamism between the various post-translational modiﬁ-
cations involved.
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